Browse the corpus

Walk the evidence base by book and chapter — the raw source passages that ground Ask, Differential, and the rest.

• Are short courses of antibiotic therapy as effective as standard courses for COPD exacerbations? A systematic review and meta-analysis1 passage
• Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: Evaluation in phase 3 clinical trials1 passage
• Effects of anumigilimab, an anti-G-CSF receptor mAb, after segmental LPS challenge: A Phase 1b trial in healthy volunteers1 passage
• Immunomodulatory effects of pidotimod in adults with community-acquired pneumonia undergoing standard antibiotic therapy1 passage
• Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis1 passage
• Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis1 passage
• Impact of statins on ALI/ARDS: A meta-analysis1 passage
• Individualizing duration of antibiotic therapy in community-acquired pneumonia1 passage
• Pharmacokinetic profile of beclometasone dipropionate/formoterol fumarate administered through a novel dry-powder inhaler in Chinese healthy volunteers1 passage